Sparteine (Quinolizidine Alkaloid · Antiarrhythmic · Uterotonic · CYP2D6 Probe)

Compound	Sparteine (Lupinidine)
Chemical class	Alkaloid — Quinolizidine (Tetracyclic lupane-type)
CAS	90-39-1
Primary source	Cytisus scoparius (Scotch broom / common broom), Lupinus spp. (lupins)
Key applications	Sodium/potassium channel blocker, antiarrhythmic (historical), oxytocic (uterotonic), cognitive research
Claim strength	Moderate (historical pharmaceutical; preclinical)
Typical form	Scotch broom extract; sparteine isolate; Spartocine historical pharmaceutical (withdrawn)
Buy from Herbuno	Request availability and bulk pricing →

Name origin: From Spartium (Spanish broom genus, a related plant) — reflecting the early botanical confusion between Scotch broom and Spanish broom. Also called lupinidine, reflecting its occurrence in Lupinus species. Sparteine is a tetracyclic quinolizidine alkaloid — the most complex member of the lupane-type quinolizidines, with four fused rings. Traditional use: Scotch broom (Cytisus scoparius, Sarothamni Scoparii Herba in European pharmacopoeia) has been used in European traditional medicine for cardiac conditions, oedema, and as a uterotonic. The European pharmacopoeia lists broom for “mild heart rhythm disturbances” — reflecting sparteine’s antiarrhythmic mechanism. In Ayurveda, related lupin species have been used. Pharmaceutical history: Sparteine was used as a pharmaceutical oxytocin substitute (Spartocine) for labour induction in the early-mid 20th century and as a Class Ia antiarrhythmic. It was withdrawn from pharmaceutical use in most markets due to the availability of better-characterised alternatives and CYP2D6 pharmacogenetic variability in sparteine metabolism — poor CYP2D6 metabolisers accumulate toxic sparteine levels. Sparteine remains important as a chiral auxiliary in asymmetric organic synthesis and in CYP2D6 pharmacogenetics research. Commercial source: Scotch broom extract is not currently in the Herbuno catalogue. Contact Herbuno for availability assessment.

---

Evidence for Sparteine Applications

Antiarrhythmic — sodium/potassium channel blockade: Sparteine blocks sodium channels (Phase 0 of cardiac action potential) and potassium channels (Phase 3 repolarisation) — a Class Ia antiarrhythmic mechanism shared with quinidine and procainamide (pharmaceutical). This mechanism was the basis for historical sparteine pharmaceutical use for supraventricular arrhythmias. Claim strength: Moderate (mechanism established; pharmaceutical historical use; withdrawn due to narrow TI and CYP2D6 variability).

Oxytocic / uterotonic: Sparteine produces uterine contractions via oxytocin receptor sensitisation and direct myometrial stimulation. Historically used as a labour-induction agent (Spartocine injections) before synthetic oxytocin became available. CONTRAINDICATION: Use during pregnancy, except under medical supervision for labour induction in historical contexts. Claim strength: Moderate (established pharmacological mechanism).

CYP2D6 pharmacogenetic probe: Sparteine is one of the original probe compounds used to characterise CYP2D6 pharmacogenetic polymorphism. The “sparteine/debrisoquine” polymorphism was one of the first pharmacogenetic discoveries — poor metabolisers (CYP2D6 null genotype, ~7% of European populations) accumulate toxic sparteine levels on standard doses. This finding drove the development of pharmacogenetic dosing concepts and is historically significant in clinical pharmacology. Research reference.

Nicotinic agonism (mild): Sparteine has weak nicotinic acetylcholine receptor (nAChR) agonist activity, contributing to respiratory stimulant and cardiac effects. This mechanism is much weaker than cytisine and unlikely to be relevant at supplement doses. Claim strength: Emerging.

---

Dosage & Formulator Specification

Historical pharmaceutical dose (antiarrhythmic, withdrawn): 50–200 mg sparteine IV or oral. The narrow therapeutic index and CYP2D6 variability make individual dose prediction unreliable without genotyping. Traditional broom preparations for cardiac use: European pharmacopoeia specifies Sarothamni Scoparii Herba (broom herb) at 1–3 g/day dried herb. For contemporary supplement formulations, Scotch broom extract at traditional European pharmacopoeia doses (delivering minimal sparteine) for “traditionally used to support healthy heart rhythm” positioning is the appropriate claim context — with mandatory CONTRAINDICATIONS for pregnancy and cardiac medications. Contact Herbuno for Scotch broom/Cytisus scoparius extract availability.

---

Frequently Asked Questions — Sparteine

Why was sparteine withdrawn as a pharmaceutical?
Sparteine was withdrawn from pharmaceutical markets (UK in 1998; Germany earlier) due to: (1) CYP2D6 pharmacogenetic variability — poor metabolisers (7–10% of European populations) accumulate toxic sparteine levels unpredictably on standard doses, causing severe toxicity; (2) the availability of safer, better-characterised antiarrhythmic drugs with predictable pharmacokinetics; (3) for the oxytocic application, synthetic oxytocin provided more precise dose-response control. The CYP2D6 variability issue specifically is a major formulation risk for sparteine-containing supplements in ungenotyped populations.

Is broom (Cytisus scoparius) safe as an herbal supplement?
Scotch broom at traditional European pharmacopoeia doses (1–3 g dried herb/day) has a historical safety record for short-term use in cardiac palpitations, with appropriate contraindications (pregnancy, cardiovascular disease beyond mild arrhythmias, concurrent cardiac medications). The CYP2D6 polymorphism safety concern applies to concentrated sparteine preparations more than to traditional dose broom preparations delivering small sparteine amounts. Mandatory contraindications: pregnancy, bradycardia, AV block, concurrent cardiac drug therapy (risk of additive cardiac effects).

How is sparteine used in chemistry?
Beyond pharmacology, sparteine is important in organic chemistry as a chiral diamine ligand for asymmetric synthesis — specifically for the asymmetric deprotonation of prochiral substrates using organolithium reagents (Beak’s protocol). Natural — (−)-sparteine provides the chiral environment for enantioselective reactions. This asymmetric synthesis application (chiral auxiliary) makes sparteine commercially valuable in fine chemicals and pharmaceutical manufacturing contexts entirely separate from its biological activities.

Can broom extract be combined with hawthorn for cardiac support?
Yes — this is a traditional European combination documented in herbal cardiac formulations. Hawthorn (Crataegus) provides vasodilatory and mild positive inotropic effects (oligomeric proanthocyanidins, vitexin). Broom (sparteine) provides antiarrhythmic activity via sodium channel blockade. The combination addresses different cardiac mechanisms. However, the same cardiovascular medication interaction advisories apply — this is a combination requiring appropriate supervision for patients with cardiac conditions and should carry clear contraindications for pregnancy, bradycardia, and concurrent cardiac drug therapy.

Related compounds: Cytisine, Vasicinone, Conessine, Glycyrrhizin

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery